Press coverage about Immuron (NASDAQ:IMRN) has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immuron earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.5401761440851 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Immuron (NASDAQ IMRN) opened at $5.76 on Wednesday. Immuron has a 12-month low of $4.47 and a 12-month high of $16.34.
Separately, HC Wainwright initiated coverage on Immuron in a report on Wednesday, October 18th. They set a “buy” rating and a $15.00 target price on the stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://weekherald.com/2017/11/15/immuron-imrn-getting-somewhat-positive-news-coverage-analysis-shows.html.
Immuron Company Profile
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Ltd and related companies with MarketBeat.com's FREE daily email newsletter.